Journal of NeuroVirology

, Volume 17, Issue 3, pp 288–290

Natalizumab and HSV meningitis

  • Erica Seiguer Shenoy
  • Eleftherios Mylonakis
  • Rocio M. Hurtado
  • Nagagopal Venna
Case Report

Abstract

Natalizumab (Tysabri, Biogen Idec and Elan Pharmaceuticals) is a monoclonal antibody approved for use in patients with relapsing multiple sclerosis (MS) as well as moderate to severe Crohn’s disease. We report the first case of a patient with a history of MS, on monthly natalizumab, who developed HSV-2 meningitis. We discuss the mechanism of action of natalizumab and review what is known about the reactivation of herpes infection in association with this medication. The question of herpes simplex virus (HSV) and varicella zoster virus (VZV) prophylaxis for patients is raised.

References

  1. Von Andrian UH, Engelhardt B (2003) α4 Integrins as therapeutic agents in autoimmune disease. N Engl J Med 348:68–72CrossRefGoogle Scholar
  2. Miller DH, Khan OA, Sheremata WA et al (2003) A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 348:15–23PubMedCrossRefGoogle Scholar
  3. Ghosh S, Goldin E, Gordon FH et al (2003) Natalizumab for active Chron’s disease. N Engl J Med 348:24–32PubMedCrossRefGoogle Scholar
  4. Van Assche G, Van Ranst M, Sciot R et al (2005) Progressive multifocal leukencephalopathy after natalizumab therapy for Crohn’s disease. N Engl J Med 353:362–368PubMedCrossRefGoogle Scholar
  5. Langer-Gould A, Atlas SW, Green AJ et al (2005) Progressive multifocal leukencephalopathy in a patient treated with natalizumab. N Engl J Med 353:375–381PubMedCrossRefGoogle Scholar
  6. Scheiss N, Zong J, Hayward G, Calabresi P et al. (2009) Reactivation of herpes virus in multiple sclerosis patients on natalizumab therapy [P03.163]. Poster presentation, April 29, 2009 at the American Academy of NeurologyGoogle Scholar
  7. Thursky KA, Worth LJ, Seymour JF (2005a) Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab. Br J Haematol 132:3–12CrossRefGoogle Scholar
  8. CAMMS223 Trial Investigators, Coles AJ, Compston DA, Selmaj KW, Lake SL, Moran S, Margolin DH, Norris K, Tandon PK (2008) Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 359(17):1786–1801PubMedCrossRefGoogle Scholar
  9. Thursky KA, Worth LJ, Seymour JF et al (2005b) Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab. Br J Haematol 132:3–12CrossRefGoogle Scholar
  10. Berger JR, Houff S (2008) Neurological complications of herpes simplex virus type 2 infection. Arch Neurol 65:596–600PubMedCrossRefGoogle Scholar

Copyright information

© Journal of NeuroVirology, Inc. 2011

Authors and Affiliations

  • Erica Seiguer Shenoy
    • 1
    • 3
  • Eleftherios Mylonakis
    • 1
    • 3
  • Rocio M. Hurtado
    • 1
    • 3
  • Nagagopal Venna
    • 2
  1. 1.Division of Infectious DiseasesMassachusetts General HospitalBostonUSA
  2. 2.Department of NeurologyMassachusetts General HospitalBostonUSA
  3. 3.Harvard Medical SchoolBostonUSA

Personalised recommendations